Tamiflu (Oseltamivir) News and Research

RSS
Tamiflu (oseltamivir phosphate) is an antiviral drug approved for treatment of uncomplicated influenza A and B in patients 1 year of age or older. It is also approved for prophylaxis (prevention) of influenza in people 13 years or older after household contact or at high risk for exposure during influenza season. Tamiflu is one of a group of anti-influenza drugs called neuraminidase inhibitors that act by blocking the viral enzyme neuraminidase which helps the influenza virus invade cells in the respiratory tract.
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

C&EN explains logic behind odd-sounding generic names

C&EN explains logic behind odd-sounding generic names

Tamiflu resistant flu on the rise: Study

Tamiflu resistant flu on the rise: Study

MRSA co-infection increases risk of flu-related mortality among children

MRSA co-infection increases risk of flu-related mortality among children

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Tamiflu resistant flu found in Newcastle, Australia

Tamiflu resistant flu found in Newcastle, Australia

Universal flu vaccine with super antibodies in near future

Universal flu vaccine with super antibodies in near future

Flu deaths analyzed for future lessons

Flu deaths analyzed for future lessons

New development in flu prevention & treatment

New development in flu prevention & treatment

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

CMAJ study: Increased dosage of Tamiflu required in treating H1N1 influenza patients

CMAJ study: Increased dosage of Tamiflu required in treating H1N1 influenza patients

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Roche ships additional quantities of Tamiflu oral suspension

Roche ships additional quantities of Tamiflu oral suspension

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

FDA urges consumers to exercise care on online H1N1 drug products

FDA urges consumers to exercise care on online H1N1 drug products

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

New Influenza A/H1N1 detection kit launched

New Influenza A/H1N1 detection kit launched